Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Red~Oneon May 01, 2022 9:00pm
373 Views
Post# 34646486

Here's the deal

Here's the dealWhen a sector is hot , good news generates instant positive shreprice reaction and that usually goes with all similar stocks with products or services that meet that expectation.  
 
The shareprice goes up. Once that sector cools down that instant reaction on good news doesn't necessarily pop like before. Reasons being that the sector is no longer front page news and also some good news is already built into the current shareprice....volume/interest disappears.
 
 2 years ago remember what was hot in Pharma? Companies supplying test kits, companies working on Vaccines, alternate treatments, clinics....the list goes on. That has all cooled down now.
 
In my opinion Nitric Oxide is the real deal, the next antibacterial, the new penecillin. The question is : "How long will it take until it is front page news?"
 
Getting thru a successful Phase 1 is Huge....but it doesn't mean that the Pharma industry will immedediately pick it up. It could take years. 


<< Previous
Bullboard Posts
Next >>